Impact of insulin therapy on insulin resistance and a risk for coronary heart disease and cardiovascular death in patients with type 2 diabetes
- Authors: Ametov A.S.1, Kochergina I.I.1, Ulanova K.A.1, Ametov AS1, Kochergina II1, Ulanova KA1
-
Affiliations:
- Issue: Vol 82, No 3 (2010)
- Pages: 42-46
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30560
- ID: 30560
Cite item
Full Text
Abstract
Subjects and methods. Seventy-four patients (49 women and 25 men) aged 36-78 years (mean 56.28 ± 2.58 years) with a 9.34 ± 1.12-year history of T2D were examined. The investigators made a clinical examination, studied the parameters of carbohydrate metabolism: glycated hemoglobin (HbA1c), fasting (FG) and postprandial glycemia (PPG) (2 hours after meals) and lipid metabolism, insulin resistance, microalbuminuria (MAU), and combined therapy-induced blood pressure changes. The risk for CHD was estimated from the atherogenicity index, total cholesterol/high-density lipoproteins and low-density lipoproteins/high-density lipoproteins ratios, and SCORE index.
Results. Long-term insulin therapy in combination with OSRD caused a significant improvement in carbohydrate metabolism (reductions in HbA1c by 216-23.2%, FG and PPG by 33.4-35.7%), positive lipid metabolic changes, a decrease in MAU by 0.12 ± 0.03 to 0.03 ± 0.01 g/l, with a fall of its detection rate from 73 to 27%; a considerable decline in IR from the HOMA and CARO indices (by 30-32%), as well as a significant reduction in the risk for CHD and 10-year cardiovascular death risk from the SCORE index (from 4 to 1.5-1.6%; p < 0.01).
Conclusion. Combined therapy with long-acting insulin in combination with OSRD in patients with T2D resulted in metabolic improvement and a significant reduction in the risk for CHD and 10-year cardiovascular death risk.
About the authors
Aleksandr Sergeevich Ametov
Email: endocrine@mtu-net.ru
Irina Ivanovna Kochergina
Email: kii7@yandex.ru
Kermen Alekseevna Ulanova
A S Ametov
I I Kochergina
K A Ulanova
References
- Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
- Ferranini E., Natali A., Capaldo A. et al. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997; 30: 1144-1149.
- Lakka H. M., Laaksonen D. E. et al. The metabolic syndrome and total cardiovascular disease mortality in middle-age men. J. A. M. A. 2002; 288 (21): 2709-2716.
- Fruhbeek G., Salvador J. Relation between leptin and regulatic of glucose metabolism. Diabetologia 2000; 43(1): 3-12.
- Trujillo M. E., Scherer P. E. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 2005; 257: 167-175.
- Wisse B. E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 2004; 15: 2792-2880.
- Sevter C. P., Digby J. E. et al. Regulation of tumor necrosis factor-alpha release from human adipose tissue in vitro. J. Endocrinol. 1999; 163: 33-38.
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet 1998; 352: 854-865.
- Tuomilehto J., Lindstrom J., Ericsson J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344: 1343-1350.
- Wallase T. M., Levy J. S., Mattheus D. R. Use end abuse of HOMA modeling. Diabet. Care 2004; 27(6): 1487-1495.
- Дедов И. И., Шестакова М. В. (ред.) Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 2-е изд. М.; 2006. 26-27.